# A Pharmacokinetic and Pharmacodynamic Study to Determine Blood Levels of JNJ-28431754 (Canagliflozin) in Patients With Type 2 Diabetes Mellitus

> **NCT01128985** · PHASE1 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 39 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Canagliflozin 50 mg
- **DRUG:** Canagliflozin 100 mg
- **DRUG:** Canagliflozin 300 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01128985
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** —
- **Final completion:** 2010-07
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2013-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01128985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01128985, "A Pharmacokinetic and Pharmacodynamic Study to Determine Blood Levels of JNJ-28431754 (Canagliflozin) in Patients With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01128985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*